Erdafitinib: First Global Approval

被引：106
作者：
Markham, Anthony [1 ]
机构：
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS | 2019年 / 79卷 / 09期
关键词：
INHIBITOR; JNJ-42756493; EVALUATE; EFFICACY;
D O I：
10.1007/s40265-019-01142-9
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Erdafitinib (Balversa, Janssen Pharmaceutical Companies) is a pan-fibroblast growth factor receptor (FGFR) inhibitor that was recently approved in the USA for the treatment of locally advanced or metastatic FGFR3 or FGFR2 urothelial carcinoma. The drug is also being investigated as a treatment for other cancers including cholangiocarcinoma, liver cancer, non-small cell lung cancer, prostate cancer, lymphoma and oesophageal cancer. This article summarizes the milestones in the development of erdafitinib leading to this first approval for the treatment of urothelial carcinoma.
引用
收藏
页码：1017 / 1021
页数：5
相关论文
共 50 条
  • [41] Ibrutinib: First Global Approval
    Cameron, Fiona
    Sanford, Mark
    DRUGS, 2014, 74 (02) : 263 - 271
  • [42] Neratinib: First Global Approval
    Deeks, Emma D.
    DRUGS, 2017, 77 (15) : 1695 - 1704
  • [43] Rolapitant: First Global Approval
    Syed, Yahiya Y.
    DRUGS, 2015, 75 (16) : 1941 - 1945
  • [44] Reslizumab: First Global Approval
    Markham, Anthony
    DRUGS, 2016, 76 (08) : 907 - 911
  • [45] Glasdegib: First Global Approval
    Hoy, Sheridan M.
    DRUGS, 2019, 79 (02) : 207 - 213
  • [46] Suvorexant: First Global Approval
    Yang, Lily P. H.
    DRUGS, 2014, 74 (15) : 1817 - 1822
  • [47] Linaclotide First Global Approval
    McWilliams, Vanessa
    Whiteside, Glenn
    McKeage, Kate
    DRUGS, 2012, 72 (16) : 2167 - 2175
  • [48] Vedolizumab: First Global Approval
    Poole, Raewyn M.
    DRUGS, 2014, 74 (11) : 1293 - 1303
  • [49] Isavuconazonium: First Global Approval
    McCormack, Paul L.
    DRUGS, 2015, 75 (07) : 817 - 822
  • [50] Ribociclib: First Global Approval
    Syed, Yahiya Y.
    DRUGS, 2017, 77 (07) : 799 - 807
12345